Stocks · News reference
Eikon Therapeutics announced the presentation of initial and updated clinical data for its EIK1003, EIK1004, and EIK1005 programs at the 2026 European Society for Medical Oncology (ESMO) Congress.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Eikon Therapeutics announced that its leadership team, including CEO Roger M. Perlmutter and CMO Roy Baynes, will participate in several upcoming investor conferences throughout November 2026.
Eikon Therapeutics announced updated clinical results for its TLR7/8 dual-agonist EIK1001 in combination with pembrolizumab and chemotherapy for the treatment of stage 4 non-small cell lung cancer.
Eikon Therapeutics presented updated data for EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for first-line stage 4 NSCLC at ESMO Congress. The squamous cohort showed 72% ORR and 100% DCR with 12.9-month median duration of response. The combination was well-tolerated with an adverse event profile similar to standard-of-care alone, supporting outpatient administration. The Phase 2/3 TeLuRide-008 trial is actively enrolling with interim analysis expected in 2H 2027.
Filed: 2026-10-26 AccNo: 0001193125-26-430860 Size: 210 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Eikon Therapeutics announced that seven abstracts from its clinical pipeline will be presented at the 2026 European Society for Medical Oncology Congress in Madrid. The presentations will cover updates on four clinical candidates including EIK1001 (TLR7/8 dual-agonist), EIK1003 and EIK1004 (PARP1 inhibitors), and EIK1005 (WRN helicase inhibitor) across various oncology indications including NSCLC, prostate cancer, and advanced solid tumors.